HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) CFO Rebecca Byam acquired 5,000 shares of the business’s stock in a transaction dated Friday, September 8th. The stock was bought at an average cost of $2.02 per share, with a total value of $10,100.00. Following the acquisition, the chief financial officer now owns 558,946 shares in the company, valued at approximately $1,129,070.92. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Rebecca Byam also recently made the following trade(s):
- On Wednesday, September 6th, Rebecca Byam bought 5,000 shares of HCW Biologics stock. The stock was purchased at an average cost of $1.95 per share, for a total transaction of $9,750.00.
HCW Biologics Stock Up 5.1 %
Shares of HCWB stock opened at $2.05 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.36 and a current ratio of 4.36. The firm’s 50-day moving average is $2.06 and its 200-day moving average is $1.79. The stock has a market cap of $73.66 million, a price-to-earnings ratio of -3.73 and a beta of 1.24. HCW Biologics Inc. has a 52-week low of $1.08 and a 52-week high of $2.79.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in HCWB. HighTower Advisors LLC increased its holdings in shares of HCW Biologics by 2,056.0% during the 1st quarter. HighTower Advisors LLC now owns 215,598 shares of the company’s stock worth $588,000 after acquiring an additional 205,598 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of HCW Biologics by 136.8% during the 1st quarter. BlackRock Inc. now owns 39,583 shares of the company’s stock worth $108,000 after buying an additional 22,869 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of HCW Biologics by 9.8% during the 3rd quarter. Vanguard Group Inc. now owns 95,392 shares of the company’s stock worth $218,000 after buying an additional 8,494 shares during the period. 2.79% of the stock is owned by institutional investors and hedge funds.
About HCW Biologics
HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
- Five stocks we like better than HCW Biologics
- When to Sell a Stock for Profit or Loss
- MarketBeat Week in Review – 9/4 – 9/8
- What is a Secondary Public Offering? What Investors Need to Know
- The Best 5 Small Cap AI Companies to Buy Now
- Why is the Ex-Dividend Date Significant to Investors?
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.